News

Archives for September 2011

RSS

Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51 (29 Sep 2011)

Bayer AG announced today that in the ATLAS ACS TIMI 51 trial, rivaroxaban (Xarelto, Bayer and Johnson & Johnson) had met the primary efficacy endpoint  in patients with acute coronary syndrome (ACS). The drug was associated with ”a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Meta-Analysis Explores Real World CV Risk of NSAIDs (29 Sep 2011)

A new meta-analysis sheds additional light on the cardiovascular risk of NSAIDs as used in the real world, including low doses of the most popular drugs, over short periods, and in low-risk populations. In a paper published online in PLoS Medicine, Patricia McGettigan and David Henry analyzed data from 30 case-control studies including 184,946 CV events…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Study Finds Noncardiac Sources of Positive Troponin T Tests (28 Sep 2011)

Cardiac troponin T (cTnT) is not always cardiac specific and in some cases may lead to a false-positive diagnosis of cardiac injury, according to a study in the Journal of the American College of Cardiology. The study was prompted by a case seen by a senior clinician at the Mayo Clinic in which a patient, who…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Experience Counts in Carotid Artery Stenting (27 Sep 2011)

Experience really does count when it comes to carotid artery stenting, and that may be a big problem, since most current operators do not have substantial experience with the procedure.

Statins for Primary Prevention: The Debate Continues (26 Sep 2011)

Several leading cardiologists have taken issue with the assertion made by Rita Redberg and the editors of the Archives of Internal Medicine that using statins for primary prevention is an example “of the widespread use of medications with known adverse effects despite the absence of data for patient benefit for these indications.” In a research letter published in…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Rivaroxaban (Xarelto) Gets Positive Recommendation for AF and DVT in Europe (23 Sep 2011)

The European Committee for Medicinal Products for Human Use (CHMP) has recommended that rivaroxaban (Xarelto) be approved for the prevention of stroke and systemic embolism in AF, according to Bayer HealthCare. CHMP has also recommended the drug’s approval for the treatment of DVT and for the prevention of recurrent DVT and PE following acute DVT….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Dronedarone (Multaq) Gets Another Drubbing in Europe (22 Sep 2011)

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended new restrictions on dronedarone (Multaq), Sanofi’s embattled and controversial antiarrhythmic drug. CHMP says that dronedarone should only be used for maintaining sinus rhythm in patients with paroxysmal or persistent AF after successful cardioversion. The drug should no longer be used in…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Diet Drugs Get a New Slim Chance at Approval (22 Sep 2011)

Contrave, the investigational diet pill combination of naltrexone and bupropion, has been granted a possible new lease on life by the FDA. In January of this year, the FDA issued a complete response letter to Orexigen, the drug’s sponsor. Now Orexigen says that it has received guidance from the FDA that could lead to approval of the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

More Data but No Answers About Platelet Function Testing (21 Sep 2011)

The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn’t answer any of the key questions about the possible role of platelet function testing in clinical practice. In a paper published in JAMA, Guido Parodi and colleagues report on 1,789 ACS patients who underwent PCI and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Significant Declines Observed in Cardiovascular Procedures Performed in Hospitals (20 Sep 2011)

More evidence is starting to emerge that the overall volume of cardiovascular procedures in U.S. hospitals is in decline. The trend should come as no surprise to those who have been following news about cardiovascular medicine in recent years, as the field has been repeatedly struck by debate, scandal, and controversy related to the potential…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.